Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FQAJJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,849
Award facts
- Contract value 100% obligated
- $6,848.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $6,848.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units with an ultimate completion date of September 30, 2025. This delivery order was issued without a set-aside designation and will be performed in Park Ridge, Illinois, where the vendor is headquartered. Xolair (omalizumab) is a monoclonal antibody injection used primarily in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a specialty pharmaceutical product within the company's broader medical supply portfolio.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and extending through November 2026. As a woman-owned small business pharmaceutical wholesaler, DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, distributing an extensive range of branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities nationwide. The company's extensive contract history with the DLA demonstrates its established capability to deliver specialized pharmaceutical products to military health systems.
Quick answers
Who was awarded contract SPE2DB25FQAJJ?
SPE2DB25FQAJJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 9, 2025.
How much is contract SPE2DB25FQAJJ worth?
The government has obligated $6,849 on SPE2DB25FQAJJ.
Is contract SPE2DB25FQAJJ an order under another contract?
Yes. SPE2DB25FQAJJ is a delivery order under SPE2DB25D9305, an indefinite delivery contract.
Was contract SPE2DB25FQAJJ competed?
The extent of competition for SPE2DB25FQAJJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award